91¸£Àû

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections.

Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage. The candidate, which will be developed by Poolbeg as POLB 002, was developed at the 91¸£Àû and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock.

Press release (17 January 2022)